NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $3.82 +0.37 (+10.72%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.52▼$3.9250-Day Range$2.31▼$3.8252-Week Range$1.25▼$6.23Volume2.80 million shsAverage Volume1.98 million shsMarket Capitalization$347.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aquestive Therapeutics alerts: Email Address Aquestive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside105.1% Upside$7.83 Price TargetShort InterestBearish11.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.22 out of 5 starsMedical Sector793rd out of 936 stocksPharmaceutical Preparations Industry371st out of 436 stocks 3.6 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.39% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 35.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 2.4 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Aquestive Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows6 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.85% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to grow in the coming year, from ($0.49) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -9.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -9.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Aquestive Therapeutics Stock (NASDAQ:AQST)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More AQST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQST Stock News HeadlinesJuly 27 at 1:14 AM | americanbankingnews.comBrokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $7.83July 26 at 4:43 PM | seekingalpha.comAQST Aquestive Therapeutics, Inc.July 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 26 at 4:43 PM | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Anaphylm’s Promising Developments and Market PotentialJuly 25 at 8:00 AM | globenewswire.comAquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration StudyJuly 23, 2024 | globenewswire.comAquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ETJuly 18, 2024 | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest UpdateJune 27, 2024 | globenewswire.comAquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 3, 2024 | globenewswire.comAquestive Therapeutics Announces Executive Appointments and Builds Commercial CapabilitiesMay 28, 2024 | finance.yahoo.comAquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy ConferenceMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Solid Finances and Promising Anaphylm™ ProspectsMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call TranscriptMay 9, 2024 | globenewswire.comAquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 9, 2024 | finance.yahoo.comAquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)May 8, 2024 | wsj.comAquestive Therapeutics Inc.See More Headlines Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$7.83 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+105.1%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,870,000.00 Net Margins-55.85% Pretax Margin-55.38% Return on EquityN/A Return on Assets-37.93% Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio5.85 Sales & Book Value Annual Sales$50.58 million Price / Sales6.88 Cash FlowN/A Price / Cash FlowN/A Book Value($1.59) per share Price / Book-2.40Miscellaneous Outstanding Shares91,040,000Free Float83,892,000Market Cap$347.77 million OptionableOptionable Beta2.80 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Daniel Barber (Age 48)CEO, President & Director Comp: $1.06MMr. A. Ernest Toth Jr. (Age 65)Chief Financial Officer Comp: $667.19kMs. Lori J. Braender BSBA (Age 68)Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $713.22kMs. Cassie Jung (Age 44)Senior Vice President of Operations Mr. Alexander Mark Schobel (Age 65)Chief Innovation & Technology Officer Comp: $672.69kDr. Stephen Wargacki (Age 45)Chief Science Officer Mr. Peter E. Boyd (Age 58)Senior Vice President of IT, HR & Communications Dr. Gary H. Slatko M.D. (Age 66)MBA, Chief Medical Officer Dr. Carl N. Kraus M.D. (Age 54)Chief Medical Officer Mr. Robert Charles ArnoldVP of Finance, Controller & Assistant SecretaryMore ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSChiasmaNASDAQ:CHMAscPharmaceuticalsNASDAQ:SCPHOptiNoseNASDAQ:OPTNChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCSold 6,132 shares on 7/26/2024Ownership: 0.266%Bank of New York Mellon CorpBought 228,351 shares on 7/26/2024Ownership: 0.251%Virtu Financial LLCBought 70,666 shares on 5/20/2024Ownership: 0.113%Lazard Asset Management LLCBought 15,601 shares on 5/15/2024Ownership: 0.032%Acadian Asset Management LLCSold 16,917 shares on 5/10/2024Ownership: 0.586%View All Insider TransactionsView All Institutional Transactions AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $2.02 at the beginning of 2024. Since then, AQST stock has increased by 89.1% and is now trading at $3.82. View the best growth stocks for 2024 here. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.08. The business earned $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' top institutional investors include Legato Capital Management LLC (0.27%), Bank of New York Mellon Corp (0.25%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Peter E Boyd and Lori J Braender. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO) and Organigram (OGI). This page (NASDAQ:AQST) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
